Qiagen N.V. Share Price Deutsche Boerse AG
Equities
QIA
NL0015001WM6
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
40.23 EUR | +0.05% | -4.21% | -0.73% |
05-21 | QIAGEN NV : Berenberg maintains a Buy rating | ZD |
05-15 | Qiagen's Updated Clinical Decision Support Platform Secures EU Certification | MT |
Sales 2024 * | 2.01B 1.85B 158B | Sales 2025 * | 2.14B 1.97B 168B | Capitalization | 9.7B 8.95B 762B |
---|---|---|---|---|---|
Net income 2024 * | 407M 375M 31.96B | Net income 2025 * | 450M 415M 35.33B | EV / Sales 2024 * | 4.96 x |
Net Debt 2024 * | 251M 231M 19.67B | Net cash position 2025 * | 257M 237M 20.22B | EV / Sales 2025 * | 4.42 x |
P/E ratio 2024 * |
23.6
x | P/E ratio 2025 * |
21.3
x | Employees | 5,900 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.86% |
Latest transcript on Qiagen N.V.
1 day | +0.05% | ||
1 week | -4.21% | ||
Current month | +4.01% | ||
1 month | +4.41% | ||
3 months | +0.24% | ||
6 months | +4.73% | ||
Current year | -0.73% |
Managers | Title | Age | Since |
---|---|---|---|
Thierry Bernard
CEO | Chief Executive Officer | 60 | 31/01/15 |
Metin Colpan
FOU | Founder | 69 | 28/04/96 |
Roland Sackers
DFI | Director of Finance/CFO | 56 | 31/12/98 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 74 | 31/05/11 | |
Metin Colpan
FOU | Founder | 69 | 28/04/96 |
Lawrence Rosen
CHM | Chairman | 66 | 25/06/13 |
Date | Price | Change | Volume |
---|---|---|---|
24/05/24 | 40.23 | +0.05% | 500 |
23/05/24 | 40.21 | -0.37% | 160 |
22/05/24 | 40.36 | -2.86% | 997 |
21/05/24 | 41.55 | -1.26% | 425 |
20/05/24 | 42.08 | +0.19% | 90 |
Delayed Quote Deutsche Boerse AG, May 24, 2024 at 09:17 am
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+45.66% | 40.65B | |
-10.72% | 27.12B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- QGEN Stock
- QIA Stock